{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T15:29:58Z","timestamp":1768577398790,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82301189"],"award-info":[{"award-number":["82301189"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["2023-YBSF-510"],"award-info":[{"award-number":["2023-YBSF-510"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-024-03779-x","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T08:43:35Z","timestamp":1732610615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tocilizumab for the management of corticosteroid-resistant GO combined with OMG: a case series"],"prefix":"10.1186","volume":"24","author":[{"given":"Chenjun","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaobo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qilin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7206-452X","authenticated-orcid":false,"given":"Yangjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"issue":"2","key":"3779_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41574-019-0305-4","volume":"16","author":"PN Taylor","year":"2020","unstructured":"Taylor PN, Zhang L, Lee RWJ, Muller I, Ezra DG, Dayan CM, Kahaly GJ, Ludgate M. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol. 2020;16(2):104\u201316.","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"3779_CR2","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3174\/ajnr.A3029","volume":"33","author":"AC Gon\u00e7alves","year":"2012","unstructured":"Gon\u00e7alves AC, Silva LN, Gebrim EM, Monteiro ML. Quantification of orbital apex crowding for screening of dysthyroid optic neuropathy using multidetector CT. AJNR Am J Neuroradiol. 2012;33(8):1602\u20137.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"4","key":"3779_CR3","doi-asserted-by":"publisher","first-page":"616","DOI":"10.18240\/ijo.2021.04.20","volume":"14","author":"R Sun","year":"2021","unstructured":"Sun R, Zhou HF, Fan XQ. Ocular surface changes in Graves\u2019 ophthalmopathy. Int J Ophthalmol. 2021;14(4):616\u201321.","journal-title":"Int J Ophthalmol"},{"issue":"2","key":"3779_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/1120672119873841","volume":"31","author":"M Kim","year":"2021","unstructured":"Kim M, Chang JH, Lee NK. Quantitative analysis of extraocular muscle volume and exophthalmos reduction after radiation therapy to treat Graves\u2019 ophthalmopathy: a pilot study. Eur J Ophthalmol. 2021;31(2):340\u20135.","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"3779_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12886-020-01431-y","volume":"20","author":"R Ma","year":"2020","unstructured":"Ma R, Cheng Y, Gan L, Zhou X, Qian J. Histopathologic study of extraocular muscles in thyroid-associated ophthalmopathy coexisting with ocular myasthenia gravis: a case report. BMC Ophthalmol. 2020;20(1):166.","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"3779_CR6","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jocn.2007.09.028","volume":"15","author":"V Zouvelou","year":"2008","unstructured":"Zouvelou V, Potagas C, Karandreas N, Rentzos M, Papadopoulou M, Zis VP, Vassilopoulos D. Concurrent presentation of ocular myasthenia and euthyroid Graves ophthalmopathy: a diagnostic challenge. J Clin Neurosci. 2008;15(6):719\u201320.","journal-title":"J Clin Neurosci"},{"issue":"3","key":"3779_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/IIO.0000000000000277","volume":"59","author":"KD Bojikian","year":"2019","unstructured":"Bojikian KD, Francis CE. Thyroid Eye Disease and Myasthenia Gravis. Int Ophthalmol Clin. 2019;59(3):113\u201324.","journal-title":"Int Ophthalmol Clin"},{"issue":"26","key":"3779_CR8","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375(26):2570\u201381.","journal-title":"N Engl J Med"},{"issue":"3","key":"3779_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz NL, Massey J, et al. International Consensus Guidance for Management of Myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"key":"3779_CR10","first-page":"477","volume":"92","author":"GB Bartley","year":"1994","unstructured":"Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc. 1994;92:477\u2013588.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"3779_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3389\/fendo.2018.00801","volume":"9","author":"R An","year":"2018","unstructured":"An R, Li Y, Yang B, Wang H, Xu Y. Rare co-occurrence of ocular myasthenia gravis and thyroid-Associated Orbitopathy (Ophthalmopathy) in an individual with hypothyroidism. Front Endocrinol (Lausanne). 2018;9:801.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"3779_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/mus.27118","volume":"63","author":"B Claytor","year":"2021","unstructured":"Claytor B, Li Y. Challenges in diagnosing coexisting ocular myasthenia gravis and thyroid eye disease. Muscle Nerve. 2021;63(5):631\u20139.","journal-title":"Muscle Nerve"},{"issue":"1","key":"3779_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s12883-020-02022-6","volume":"20","author":"J Tang","year":"2020","unstructured":"Tang J, Qin C. Rare concurrent ocular myasthenia gravis and Graves\u2019 ophthalmopathy in a man with Poland syndrome: a case report. BMC Neurol. 2020;20(1):444.","journal-title":"BMC Neurol"},{"issue":"4","key":"3779_CR14","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marin\u00f2 M, Vaidya B, Wiersinga WM. The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol. 2021;185(4):G43\u201367.","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"3779_CR15","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023\u201336.","journal-title":"Lancet Neurol"},{"key":"3779_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","volume":"195","author":"JV Perez-Moreiras","year":"2018","unstructured":"Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Romo Lopez A, Rodr\u00edguez Alvarez FM, Castillo Laguarta JM, Del Estad Cabello A, Gessa Sorroche M, Espa\u00f1a Gregori E, et al. Efficacy of Tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves Orbitopathy: a Randomized Clinical Trial. Am J Ophthalmol. 2018;195:181\u201390.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"3779_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/09273948.2018.1545914","volume":"28","author":"T Maldiney","year":"2020","unstructured":"Maldiney T, Deschasse C, Bielefeld P. Tocilizumab for the management of corticosteroid-resistant mild to severe Graves\u2019 Ophthalmopathy, a report of three cases. Ocul Immunol Inflamm. 2020;28(2):281\u20134.","journal-title":"Ocul Immunol Inflamm"},{"key":"3779_CR18","doi-asserted-by":"publisher","first-page":"1186105","DOI":"10.3389\/fendo.2023.1186105","volume":"14","author":"G Boutzios","year":"2023","unstructured":"Boutzios G, Chatzi S, Goules AV, Mina A, Charonis GC, Vlachoyiannopoulos PG, Tzioufas AG. Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves\u2019 orbitopathy: an observational study. Front Endocrinol (Lausanne). 2023;14:1186105.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3779_CR19","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.2147\/JIR.S423098","volume":"16","author":"TT Yang","year":"2023","unstructured":"Yang TT, Wang ZY, Fan ZX, Yuan BY, Ma L, Lu JF, Liu PJ, He Y, Liu GZ. A pilot study on Tocilizumab in Very-Late-Onset Myasthenia Gravis. J Inflamm Res. 2023;16:5835\u201343.","journal-title":"J Inflamm Res"},{"issue":"6","key":"3779_CR20","doi-asserted-by":"publisher","first-page":"e14793","DOI":"10.1111\/cns.14793","volume":"30","author":"Z Ruan","year":"2024","unstructured":"Ruan Z, Tang Y, Gao T, Li C, Guo R, Sun C, Huang X, Li Z, Chang T. Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis. CNS Neurosci Ther. 2024;30(6):e14793.","journal-title":"CNS Neurosci Ther"},{"issue":"4","key":"3779_CR21","doi-asserted-by":"publisher","first-page":"362","DOI":"10.5603\/EP.2015.0046","volume":"66","author":"N Sawicka-Gutaj","year":"2015","unstructured":"Sawicka-Gutaj N, Bednarczuk T, Daroszewski J, Walig\u00f3rska-Stachura J, Mi\u015bkiewicz P, Sowi\u0144ski J, Bolanowski M, Rucha\u0142a M. GO-QOL\u2013disease-specific quality of life questionnaire in Graves\u2019 orbitopathy. Endokrynol Pol. 2015;66(4):362\u20136.","journal-title":"Endokrynol Pol"},{"issue":"2","key":"3779_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141\u20139.","journal-title":"Muscle Nerve"},{"key":"3779_CR23","doi-asserted-by":"crossref","unstructured":"Arcellana AES, Adiao KJB, Buenaluz-Sedurante M. Dual attack: targeting the rare co-occurrence of myasthenia gravis and Graves\u2019 disease with radioactive iodine therapy. Endocrinol Diabetes Metab Case Rep. 2021; 2021.","DOI":"10.1530\/EDM-21-0046"},{"issue":"2","key":"3779_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/archneur.60.2.243","volume":"60","author":"MJ Kupersmith","year":"2003","unstructured":"Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol. 2003;60(2):243\u20138.","journal-title":"Arch Neurol"},{"issue":"2","key":"3779_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaut.2010.12.001","volume":"36","author":"R Aricha","year":"2011","unstructured":"Aricha R, Mizrachi K, Fuchs S, Souroujon MC. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun. 2011;36(2):135\u201341.","journal-title":"J Autoimmun"},{"issue":"6","key":"3779_CR26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.nmd.2017.03.007","volume":"27","author":"DI Jonsson","year":"2017","unstructured":"Jonsson DI, Pirskanen R, Piehl F. Beneficial effect of tocilizumab in myasthenia gravis refractory to Rituximab. Neuromuscul Disord. 2017;27(6):565\u20138.","journal-title":"Neuromuscul Disord"},{"key":"3779_CR27","doi-asserted-by":"publisher","first-page":"577634","DOI":"10.1016\/j.jneuroim.2021.577634","volume":"358","author":"A Uzawa","year":"2021","unstructured":"Uzawa A, Akamine H, Kojima Y, Ozawa Y, Yasuda M, Onishi Y, Sawai S, Kawasaki K, Asano H, Ohyama S, et al. High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis. J Neuroimmunol. 2021;358:577634.","journal-title":"J Neuroimmunol"},{"issue":"3","key":"3779_CR28","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/cei.13546","volume":"203","author":"A Uzawa","year":"2021","unstructured":"Uzawa A, Kuwabara S, Suzuki S, Imai T, Murai H, Ozawa Y, Yasuda M, Nagane Y, Utsugisawa K. Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol. 2021;203(3):366\u201374.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"3779_CR29","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/cei.12272","volume":"176","author":"A Uzawa","year":"2014","unstructured":"Uzawa A, Kawaguchi N, Himuro K, Kanai T, Kuwabara S. Serum cytokine and chemokine profiles in patients with myasthenia gravis. Clin Exp Immunol. 2014;176(2):232\u20137.","journal-title":"Clin Exp Immunol"},{"key":"3779_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.clineuro.2017.04.012","volume":"157","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Zhang Y, Li H, Jia X, Zhang X, Xia Y, Wang Y, Fu L, Xiao C, Geng D. Increased expression of P2X7 receptor in peripheral blood mononuclear cells correlates with clinical severity and serum levels of Th17-related cytokines in patients with myasthenia gravis. Clin Neurol Neurosurg. 2017;157:88\u201394.","journal-title":"Clin Neurol Neurosurg"},{"key":"3779_CR31","first-page":"40","volume":"9","author":"A Steensberg","year":"2003","unstructured":"Steensberg A. The role of IL-6 in exercise-induced immune changes and metabolism. Exerc Immunol Rev. 2003;9:40\u20137.","journal-title":"Exerc Immunol Rev"},{"issue":"2","key":"3779_CR32","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1113\/expphysiol.2012.068189","volume":"98","author":"SS Welc","year":"2013","unstructured":"Welc SS, Clanton TL. The regulation of interleukin-6 implicates skeletal muscle as an integrative stress sensor and endocrine organ. Exp Physiol. 2013;98(2):359\u201371.","journal-title":"Exp Physiol"},{"issue":"1","key":"3779_CR33","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1172\/JCI118398","volume":"97","author":"T Tsujinaka","year":"1996","unstructured":"Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, Tanaka K, Katsume A, Ohsugi Y, Shiozaki H, et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest. 1996;97(1):244\u20139.","journal-title":"J Clin Invest"},{"key":"3779_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-014-0179-6","volume":"3","author":"M Maurer","year":"2015","unstructured":"Maurer M, Bougoin S, Feferman T, Frenkian M, Bismuth J, Mouly V, Clairac G, Tzartos S, Fadel E, Eymard B, et al. IL-6 and akt are involved in muscular pathogenesis in myasthenia gravis. Acta Neuropathol Commun. 2015;3:1.","journal-title":"Acta Neuropathol Commun"},{"issue":"8","key":"3779_CR35","first-page":"2976","volume":"81","author":"M Salvi","year":"1996","unstructured":"Salvi M, Girasole G, Pedrazzoni M, Passeri M, Giuliani N, Minelli R, Braverman LE, Roti E. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves\u2019 disease. J Clin Endocrinol Metab. 1996;81(8):2976\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1\u20132","key":"3779_CR36","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jneuroim.2005.09.001","volume":"170","author":"R Saito","year":"2005","unstructured":"Saito R, Onodera H, Tago H, Suzuki Y, Shimizu M, Matsumura Y, Kondo T, Itoyama Y. Altered expression of chemokine receptor CXCR5 on T cells of myasthenia gravis patients. J Neuroimmunol. 2005;170(1\u20132):172\u20138.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"3779_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1365-3083.2012.02703.x","volume":"76","author":"Z Wang","year":"2012","unstructured":"Wang Z, Wang W, Chen Y, Wei D. T helper type 17 cells expand in patients with myasthenia-associated thymoma. Scand J Immunol. 2012;76(1):54\u201361.","journal-title":"Scand J Immunol"},{"key":"3779_CR38","doi-asserted-by":"crossref","unstructured":"Fang S, Zhang S, Huang Y, Wu Y, Lu Y, Zhong S, Liu X, Wang Y, Li Y, Sun J et al. Evidence for associations between Th1\/Th17 hybrid phenotype and altered lipometabolism in very severe Graves Orbitopathy. J Clin Endocrinol Metab. 2020; 105(6).","DOI":"10.1210\/clinem\/dgaa124"},{"issue":"3","key":"3779_CR39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jbspin.2016.04.008","volume":"84","author":"N Martis","year":"2017","unstructured":"Martis N, Chirio D, Queyrel-Moranne V, Zenut MC, Rocher F, Fuzibet JG. Tocilizumab-induced hypofibrinogenemia: a report of 7 cases. Joint Bone Spine. 2017;84(3):369\u201370.","journal-title":"Joint Bone Spine"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03779-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-024-03779-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03779-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T09:02:52Z","timestamp":1732611772000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-024-03779-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3779"],"URL":"https:\/\/doi.org\/10.1186\/s12886-024-03779-x","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Second Affiliated Hospital of Air Force Medical University and carried out in compliance with the Declaration of Helsinki. Written informed consent was obtained from all the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The written consents for publication have been obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"510"}}